Masato Abei

Tsukuba, 3058575, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Safety margin of radiofrequency ablation for hepatocellular carcinoma: a prospective study using magnetic resonance imaging with superparamagnetic iron oxide.

Safety margin of radiofrequency ablation for hepatocellular carcinoma: a prospective study using magnetic resonance imaging with superparamagnetic iron oxide.

Journal: Japanese journal of radiology

Published: December 21, 2018

Editorial: Oncolytic Virus and Gene Thearapy Application: Update 2018.

Editorial: Oncolytic Virus and Gene Thearapy Application: Update 2018.

Journal: Current cancer drug targets

Published: February 20, 2018

Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma.

Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma.

Journal: Cancer science

Published: October 04, 2016

Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma.

Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: July 21, 2016

Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers.

Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers.

Journal: Current cancer drug targets

Published: May 23, 2016

Oncolytic Viruses: The Best is Yet to Come.

Oncolytic Viruses: The Best is Yet to Come.

Journal: Current cancer drug targets

Published: May 23, 2016

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation.

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation.

Journal: Oncoscience

Published: November 05, 2014

Proton beam therapy for unresectable intrahepatic cholangiocarcinoma.

Proton beam therapy for unresectable intrahepatic cholangiocarcinoma.

Journal: Journal of gastroenterology and hepatology

Published: October 27, 2014

Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib.

Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib.

Journal: BMC cancer

Published: October 05, 2014

Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status.

Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status.

Journal: Medical oncology (Northwood, London, England)

Published: September 22, 2014

Association between pretreatment retention rate of indocyanine green 15 min after administration and life prognosis in patients with HCC treated by proton beam therapy.

Association between pretreatment retention rate of indocyanine green 15 min after administration and life prognosis in patients with HCC treated by proton beam therapy.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: May 30, 2014

Antitumor effects of a sirtuin inhibitor, tenovin-6, against gastric cancer cells via death receptor 5 up-regulation.

Antitumor effects of a sirtuin inhibitor, tenovin-6, against gastric cancer cells via death receptor 5 up-regulation.

Journal: PloS one

Published: October 28, 2013

Showing 1-12 of 16

Last Updated: 09/26/2026